Merck & Co. Inc., of Whitehouse Station, N.J., said data from the pivotal phase III fracture outcomes study for odanacatib, an investigational once-weekly cathepsin K inhibitor, in postmenopausal women with osteoporosis met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and nonvertebral fractures compared with placebo.